Physician profile
Daniel J Stein
NPI 1548212244
$1,199.35
in general payments reported to CMS, 2019-2025
24 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $113 · 2021: $153 · 2022: $297 · 2023: $184 · 2024: $205 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181.49 | 2019-2024 | |
| Coopersurgical, INC. | $124.20 | 2022-2024 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Hologic Sales and Service, LLC | $91.48 | 2020-2025 | Myosure Tissue Removal Device, Novasure |
| Astellas Pharma US INC | $84.66 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $69.72 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $68.49 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.39 | 2019-2025 | |
| Exact Sciences Corporation | $58.72 | 2023-2024 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $56.78 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $49.91 | 2021-2022 | |
| Shield Therapeutics INC | $46.45 | 2023 | Accrufer |
| Meditrina | $46.20 | 2021-2022 | |
| Gynesonics, INC. | $30.28 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $27.39 | 2019-2024 | Slynd |
| Minerva Surgical, INC | $26.57 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $26.25 | 2019 | |
| Allergan, INC. | $23.38 | 2019 | |
| Daiichi Sankyo INC. | $23.30 | 2021 | |
| Millicent US INC | $21.66 | 2025 | Femlyv |
| Therapeuticsmd, INC. | $21.33 | 2022 | |
| Sumitomo Pharma America, INC. | $19.20 | 2023 | Myfembree |
| Merck Sharp & Dohme LLC | $16.21 | 2022 | |
| Covidien LP | $12.17 | 2019 | |
| Organon LLC | $12.12 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.